Skip to Content

Join the 'Neupogen' group to help and get support from people like you.

Neupogen News

FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)

Posted 6 Mar 2015 by Drugs.com

March 6, 2015 – The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States. Biological products are generally derived from a living organism. They can come from many sources, including humans, animals, microorganisms or yeast. A biosimilar product is a biological product that is approved based on a showing that it ...

Biosimilars in 2015 - What Can We Expect?

Posted 7 Jan 2015 by Drugs.com

On Wednesday, January 7th, the FDA Oncologic Drugs Advisory Committee unanimously recommended approval of Sandoz’s EP2006, a biosimilar for filgrastim (Neupogen). EP2006 is a recombinant granulocyte colony-stimulating factor used to boost white blood cells after cancer treatments that deplete these necessary infection-fighting cells. If FDA-approved, this would be the first true biosimilar in the ...

Ask a Question

Further Information

Related Condition Support Groups

Neutropenia Associated with Chemotherapy, Bone Marrow Transplantation, Neutropenia, Peripheral Progenitor Cell Transplantation, Neutropenia Associated with Radiation

Neupogen Patient Information at Drugs.com